Biotech News
MeiraGTx Reports Third Quarter 2026 Financial and Operational Results
Submission of Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP) expected in December 2026 Submission of full Biologics License Application (BLA) to the U.S.
